HIV Genotyping and Phenotyping for Drug Resistance Effective Date December 31, 2014 Original Policy Date December 31, 2014
|
|
- Crystal Russell
- 6 years ago
- Views:
Transcription
1 BSC2.09 Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory HIV Genotyping and Phenotyping for Drug Resistance Effective Date December 31, 2014 Original Policy Date December 31, 2014 Next Review Date December 2015 Description Human immunodeficiency virus (HIV) is a ribonucleic acid virus characterized by a high replication and mutation rate throughout all stages of infection. Due to this high replication and mutation rate, resistance to antiretroviral drug therapy may develop. Drug resistance remains a major limitation to successful HIV therapy. Resistance testing can improve treatment outcomes in an infected individual. Genotypic testing detects drug resistance mutations, while phenotypic testing measures the amount of drug necessary to inhibit or suppress viral replication. In addition, genotype results have been proposed to predict the phenotype by identifying similar genotypes from a large database of other HIV genotypes for which the phenotypes are known. Related Policies Laboratory Testing for HIV Tropism Policy Human immunodeficiency virus (HIV) genotyping or phenotyping may be considered medically necessary for any of the following indications: Failed course of antiviral therapy Suboptimal viral load reduction after antiviral therapy Acute or recent infection treatment decision guidance Antiretroviral naїve patients entering treatment The following are considered investigational: Routine use of combined genotyping and phenotyping Drug susceptibility phenotype prediction using genotypic comparison to a known genotypic/phenotypic database Policy Guidelines HIV genotyping and phenotyping are commonly performed in reference laboratories. Benefit Application Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the 1
2 contract language, the contract language will control. Please refer to the member's contract benefits in effect at the time of service to determine coverage or noncoverage of these services as it applies to an individual member. Some state or federal mandates (e.g., Federal Employee Program (FEP)) prohibit Plans from denying Food and Drug Administration (FDA) - approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone. Rationale The human immunodeficiency virus (HIV) is characterized by a high replication rate. The reverse transcription enzyme required for replication is error prone, resulting in a high rate of mutations, further leading to a swarm of related viruses (termed quasi-species) within the host. It is estimated that every possible single-point mutation occurs more than 10,000 times per day in infected individuals. While some of the mutations may be innocuous or render the virus unviable, others may confer resistance to antiviral drugs. It is likely that clones of drug-resistant viruses exist even before any antiviral therapy, but due to an associated replication or competitive disadvantage compared to the wild-type virus, the resistant clone only represents a small proportion of the total viral load. However, in the presence of antiviral drugs that selectively eliminate the wild-type virus, a resistant clone may rapidly emerge as the dominant quasi-species. Over time, this resistant clone may accumulate additional secondary mutations which overcome the original replication or competitive disadvantage. Virological treatment failure (i.e., increasing viral loads) may result. Alternatively, due to the widespread use of antiviral therapy, patients may become infected with a resistant strain. Current recommendations for initial drug therapy suggest the use of combination therapy with antivirals with different mechanisms of action designed to reduce the viral load to as low a level as possible. The four classes of agents available include: Nucleoside reverse transcription inhibitors (NRTI) Non-nucleoside reverse transcription inhibitors (NNRTI) Protease inhibitors (PI) Fusion inhibitors This therapeutic principle is based on the concept that cessation of detectable HIV replication decreases the opportunity for accumulation of mutations that may give rise to drug-resistant viral variants. These regimens are referred to as highly active antiretroviral therapy (HAART). If initial drug therapy fails, as evidenced by rising HIV viral loads, it is likely that the emergent virus is drug resistant, unless failure is related to drug non-compliance. At this point, physicians must devise a salvage therapy, using drugs to which the virus likely remains sensitive. While drug resistance is most common in the setting of prior failed therapy, there have been reports of initial infection of drug-resistant strains, particularly to zidovudine, a drug that has been widely used since the 1980s. Human immunodeficiency virus genotyping (i.e., gene sequencing) has revealed specific point mutations or combinations of mutations in the enzymes targeted by these drugs, i.e., viral protease and reverse transcriptase. These mutations may be associated with drug resistance. For example, a single-point mutation in HIV can confer high-level resistance to the antiviral lamivudine (an NRTI) and certain NNRTIs. In contrast, high-level resistance to 2
3 zidovudine (an NRTI) and certain protease inhibitors requires accumulation of three or more mutations. When only a single mutation is required for resistance, resistance may emerge within one month of treatment initiation. For this reason, these drugs are never used as monotherapy. In contrast, when multiple mutations are required, resistance may emerge only after months to years of therapy. Mutations that are common to several different drugs within a group will confer cross resistance. For example, cross resistance among the protease inhibitor drugs is common. HIV phenotyping directly measures drug resistance by identifying the drug concentration necessary to inhibit virus replications, usually by 50. While phenotyping is a more direct measure of drug resistance compared to genotyping, the technique is labor intensive and technically challenging. Results of genotypes have also been used to predict the phenotype by identifying similar genotypes from a large database of other HIV genotypes for which the phenotypes are known. This data analysis is known as the VirtualPhenotype. The evolving understanding of the clinical significance of drug resistance has created interest in both HIV genotyping and phenotyping to identify active drug regimens in the following clinical settings: To determine the most effective salvage therapy in patients with drug resistance. For example, the virus seen during treatment failure may not be resistant to all drugs in a regimen To confirm that antiviral drug failure is due to drug resistance and not patient noncompliance To determine viral resistance at initial diagnosis of HIV infection Genotype and Phenotype in Patients Failing Drug Therapy A variety of randomized trials have compared phenotype- or genotype-directed antiviral therapies to standard care with empirically selected antiviral therapies. The primary endpoints of these studies consisted of virologic suppression at three to six months following randomization. The genotypic antiretroviral resistance testing (GART), Havana, and ARGENTA trials reported that salvage antiviral therapy directed by genotyping had improved virologic outcomes compared with standard therapy (Baxter et al., 2000; Tural et al., 2002; Cingolani et al., 2002). Only about 30% of patients achieved undetectable viral loads, and in most cases, the sustained response was short lived. Randomized studies of phenotype-directed therapy have shown less impressive results. While results of the VIRA3001 study reported a decrease in viral load in the phenotype- directed arm compared to the standard care arm, this reduction was not clinically significant by intentto-treat analysis (Cohen et al., 2002). The California Collaborative Treatment Group (CCTG 575) trial showed no difference between the two arms either in terms of reduction in viral load or undetectable virus (Haubrich et al., 2005). Three randomized studies compared the results of genotype-directed and phenotype-directed therapy. (Meynard et al., 2002; Blanco et al., 2002; Wegner et al., 2002). These studies did not clearly establish the superiority of either genotyping or phenotyping. While non-randomized studies have suggested that combined genotyping and phenotyping may provide complementary information (Parkin et al., 2002), no randomized studies have compared the combination of genotyping and phenotyping to direct therapy compared to either genotyping or phenotyping alone. As noted previously, the results of genotyping can be compared to a database to predict the phenotype. Two randomized studies have suggested that therapy directed by the predicted phenotype is comparable to phenotype- directed therapy (Mazzotta et al., 2002; Perez-Elias et al., 2002). However, since the predicted 3
4 phenotype requires a preceding genotype, the more relevant comparison would be the outcomes of combined genotype/predicted phenotype-directed therapy compared to genotype-directed therapy alone. No such study has been reported. DeLuca and colleagues (2006) reported that the benefit of genotype-guided treatment decisions continued over time in patients who failed antiviral therapy. Hirsch and colleagues (2005) noted no differences between genotyping and phenotyping in a series of 102 patients, but cautioned that the numbers of tests may not have been sufficient to detect differences. Dunn et al., (2005) reported on a randomized trial that did not demonstrate added value of phenotypic resistance in conjunction with genotypic testing in patients with virologic failure. A review article by Zolopa (2006) mentions potential problems caused by discordant results between genotyping and phenotyping and also mentions replication capacity as having potential prognostic value. A 2007 report estimated the persistence of transmitted drug resistant variants in a cohort of 14 untreated men with recent seroconversion was 4.1 years (median). In contrast, in the absence of selective drug pressure, patients with treatment-acquired drug resistance experience little persistence and drug-sensitive virus rebounds over the course of 12 to 16 weeks (Little et al., 2008). Areas with a relatively high prevalence of drug-resistant disease at diagnosis and at the time of initial treatment may find resistance testing helpful, given transmitted drug resistance is associated with a higher likelihood of virologic failure. Borroto-Esoda et al., (2007) reported the presence of resistance to the K103N mutation at baseline was statistically associated with virologic failure in both arms of a randomized controlled trial comparing two initial treatment regimens (n = 546, of whom n = 90 had some baseline resistance). Furthermore, the presence of any mutation (using genotypic resistance testing) was statistically associated with virologic failure in one treatment arm. In a second report, a subcohort (n = 208) of clinical trial patients receiving the same therapy, stated the time to virologic failure was significantly longer in patients who had no baseline resistance to NNRTIs compared to those with baseline resistance (HR 2.27, 95% CI ) (Kuritzkes et al., 2008). Therefore, the prevalence of transmitted drug resistance may be important in guiding treatment decisions. Finally, in a cohort study, Palella et al., (2009) evaluated the association between genotypic and phenotypic susceptibility testing (GPT) and its effect on survival. Results showed patients who had GPT had lower mortality rates than those who did not (2.0 verses 2.7 deaths per 100-person- years). In standard Cox models, GPT was also associated with improved survival after controlling for demographic characteristics, CD4+ cell count, HIV RNA levels and intensity of clinical follow-up. However, this study was not randomized and residual confounding may exist. Genotype and Phenotype in Treatment-Naïve Patients The prevalence in transmission of drug-resistant strains of HIV in this country ranges geographically from 5% to 26%. While there have been no controlled studies of resistance testing in treatment-naïve patients, some authors recommend either genotypic or phenotypic resistance testing in patients with acute HIV infection in geographic areas where drug-resistant strains of HIV are prevalent. In contrast, such testing is not generally recommended in patients with chronic, treatment-naïve HIV. This is based on the fact that genotypic or phenotypic testing may not detect drug-resistant species which were transmitted at the time of primary infection but have become a minor species in the absence of selective drug pressure. An alternative approach would be to reserve genotypic or phenotypic testing to those patients with chronic HIV infection who have a 4
5 suboptimal response to initial therapy. While some modeling studies suggest that resistance testing could have value in treatment-naïve patients, trials are needed to demonstrate the clinical impact. Updated guidelines recommend drug resistance testing (generally genotyping) in treatment-naïve patients; however, this recommendation is based on expert opinion (Department of Health and Human Services (DHHS), 2006). This guideline notes that resistance testing in those who have failed antiviral therapy is supported by data from clinical trials. Several studies estimated the prevalence of infection with virus resistant to at least one class of antiretroviral therapy among treatment naïve patients (enrolled in U.S.-based studies from 2000 to 2004) at 10 to 16% (Kuritzkes et al., 2008; Eshleman et al., 2007; Parker et al., 2007). One of these (15.9%) was among recent (six months or less) seroconverters (Eshleman et al., 2007). In addition, prevalences as high as 24% in U.S. populations were reported in a review (Booth and Geretti, 2007). Clinical Guideline Recommendations Both the DHHS and the International AIDS Society (IAS) published clinical guidelines regarding resistance testing (Dybul et al., 2002; U.S. Public Health Service Task Force, 2002; Yeni et al., 2002). The updated U.S. Treatment Guidelines (2008) currently recommend resistance testing with acute onset of infection, regardless of whether therapy will be initiated, in order to ascertain whether or not drug-resistant virus was transmitted. The information on which this recommendation is based was considered to be in part because transmitted drug resistance is thought to be fundamentally different from acquired (from treatment) drug resistance, both in its fitness (capacity to infect and replicate) and its persistence (does not revert to a minority species) (Booth and Geretti, 2007). Randomized trials have suggested genotype-directed and, to a lesser extent, phenotypedirected therapy may result in improved short-term virologic outcomes in patients failing or having a suboptimal response to antiretroviral therapy. While guidelines suggest either type of assay may be recommended in treatment-naïve patients with acute infection, particularly in geographic areas in which there is a high prevalence of resistant virus, this strategy has not been tested in controlled studies and therefore is considered investigational. No randomized studies have used combined genotype- and phenotypedirected therapy; therefore, this indication is considered investigational. However, the DHHS notes that there may be individual cases of such complexity that combined resistance testing may be helpful. Finally, no randomized studies have compared genotype alone with predicted phenotype (i.e., virtual phenotype ). References 1. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 14(9):F Blanco JL, Valdecillos G, Arroyo JR et al. A prospective randomized study on the usefulness of genotypic resistance tests versus real phenotypic resistance tests in heavily pretreated patients with virological failure (VIHRES study). 14th International AIDS Conference, Barcelona, Abstract TuPeB Blue Cross Blue Shield Association. Medical Policy Reference Manual. No (March 2014). 4. Booth CL & Geretti AM. Prevalence and determinants of transmitted antiretroviral 5
6 drug resistance in HIV-1 infection. J Antimicrob Chemother 2007; 59(6): Borroto-Esoda K, Waters JM, Bae AS et al. Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz. AIDS Res Hum Retroviruses 2007; 23(8): Cingolani A, Antinori A, Rizzo MG et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002; 16(3): Cohen CJ, Hunt S, Sension M et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16(4): De Luca A, Di Giambenedetto S, Cingolani A et al. Three-year clinical outcomes of resistance genotyping and expert advice: extended follow-up of the Argenta trial. Antivir Ther 2006; 11(3): Department of Health and Human Services. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October 10, Retrieved on December 3, 2014 from Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1- infected adults and adolescents. January 29, 2008; pages Retrieved on December 3, 2014 from Dunn DT, Green H, Loveday C et al. A randomized controlled trial of the value of phenotypic testing in addition to genotypic testing for HIV drug resistance: evaluation of resistance assays (ERA) trial investigators. J Acquir Immune Defic Syndr 2005;38(5): Dybul M, Fauci AS, Bartlett JG et al. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 2002; 137(5 pt 2): Eshleman SH, Husnik M, Hudelson S et al. Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection. AIDS 2007; 21(9): Haubrich RH, Keiser PH, Kemper CA et al. CCTG 575: a randomized, prospective study of phenotype testing versus standard of care for patients failing antiretroviral therapy. Antiviral Ther 2001; 6 (suppl 1), 63 Abstr 80. (Haubrich RH, Kemper CA, Hellmann NS et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS 2005; 19(3): ) 15. Hirsch HH, Drechsler H, Holbro A et al. Genotypic and phenotypic resistance testing of HIV-1 in routine clinical care. Eur J Clin Microbiol Infect Dis 2005; 24(11): Kuritzkes DR, Lalama CM, Ribaudo HJ et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 2008; 197(6): Little SJ, Frost SD, Wong JK et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008;82(11): Mazzotta F, Lo Caputo S, Torti C et al. Real vs. VirtualPhenotype: 12-month results from the GenPherex study. Ninth Conference on Retroviruses and Opportunistic 6
7 Infections. Seattle, 2002; Abstract 589-T. 19. Meynard JL, Vray M, Morand-Joubert L et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 2002;16(5): Palella FJ, Armon C, Buchacz K, et al. The asociation of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study. Ann Intern Med Jul 21; 151(2): Parker MM, Gordon D, Reilly A et al. Prevalence of drug-resistant and nonsubtype B HIV strains in antiretroviral-naїve, HIV-infected individuals in New York State. AIDS Patient Care STDS 2007; 21(9): Parkin N, Chappey C, Maroldo L et al. Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information. J Acquir Immune Defic Syndr 2002;31(2): Perez-Elias MJ, Garcia-Arata I, Munoz V et al. A randomized, prospective study of phenotype (P) versus virtual phenotype (VirtualP) testing for patients failing antiretroviral therapy. Ninth Conference on Retroviruses and Opportunistic Infections. Seattle Abstract 586-T. 24. Tural C, Ruiz L, Holtzer C et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial AIDS 2002; 16(2): U.S. Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. MMWR Recomm Rep 2002; 51(RR-18): Wegner SA, Wallace M, Aronson N et al. Long-term clinical efficacy of resistance testing: results of the CERT trial. 14th International AIDS Conference, Barcelona, Abstract ThOrB Yeni PG, Hammer SM, Carpenter CC et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society- USA Panel. JAMA 2002; 288(2): Zolopa AR. Incorporating drug-resistance measurements into the clinical management of HIV-1 infection. J Infect Dis 2006; 194(suppl 1):S Documentation Required for Clinical Review No records required Coding This Policy relates only to the services or supplies described herein. Benefits may vary according to benefit design; therefore, contract language should be reviewed before applying the terms of the Policy. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement. MN/IE The following service/procedure may be considered medically necessary in certain instances and investigational in others. Services may be medically necessary when policy criteria are met. Services are considered investigational when the policy criteria are not met or when the code describes application of a product in the position statement that is investigational. 7
8 Type Code Description Infectious agent drug susceptibility phenotype prediction using regularly updated genotypic bioinformatics Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, reverse transcriptase and protease CPT Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; first through 10 drugs tested Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; each additional drug tested (List separately in addition to code for primary procedure) HCPC None ICD-9 Procedure None ICD-10 Procedure For dates of service on or after 10/01/2015 ICD-9 Diagnosis All Diagnoses ICD-10 Diagnosis For dates of service on or after 10/01/2015 All Diagnoses Policy History This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy. Effective Date Action Reason 2/23/2000 Adopted BCBSA policy Medical Policy Committee 6/28/2007 Policy revision without position change Updated CPT codes added 7/2/2010 Policy revision with position change with title change from HIV Genotyping and Phenotyping Medical Policy Committee Medical Policy Committee 7/22/2010 Administrative update Administrative Review 8/10/2010 Administrative update Administrative Review 9/13/2010 Policy criteria revised Policy statement clarification 12/31/2014 Policy revision without position Medical Policy Committee change 8
9 Definitions of Decision Determinations Medically Necessary: A treatment, procedure or drug is medically necessary only when it has been established as safe and effective for the particular symptoms or diagnosis, is not investigational or experimental, is not being provided primarily for the convenience of the patient or the provider, and is provided at the most appropriate level to treat the condition. Investigational/Experimental: A treatment, procedure or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted. Split Evaluation: Blue Shield of California / Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a Split Evaluation, where a treatment, procedure or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances. Prior Authorization Requirements This service (or procedure) is considered medically necessary in certain instances and investigational in others (refer to policy for details). For instances when the indication is medically necessary, clinical evidence is required to determine medical necessity. For instances when the indication is investigational, you may submit additional information to the Prior Authorization Department. Within five days before the actual date of service, the Provider MUST confirm with Blue Shield that the member's health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member's eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions. Questions regarding the applicability of this policy should also be directed to the Prior Authorization Department. Please call or visit the Provider Portal The materials provided to you are guidelines used by this plan to authorize, modify, or deny care for persons with similar illness or conditions. Specific care and treatment may vary depending on individual need and the benefits covered under your contract. These Policies are subject to change as new information becomes available. 9
HIV Genotyping and Phenotyping
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationPerspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation
Perspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation Resistance testing has emerged as an important tool for antiretroviral management. Research continues to refine
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationDrug Resistance: Part 2 Application to clinical practice
World Health Organization Regional Office for the Western Pacific The aim of this biannual newsletter is to provide health workers in the Region with a brief, up-to-date summary of the latest developments
More informationHandheld Radiofrequency Spectroscopy for Intraoperative Assessment of Surgical Margins During Breast-Conserving Surgery
7.01.140 Handheld Radiofrequency Spectroscopy for Intraoperative Assessment of Surgical Margins During Breast-Conserving Surgery Section 7.0 Surgery Subsection Description Effective Date November 26, 2014
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Enfuvirtide (Fuzeon) Reference Number: CP.PHAR.41 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationMedical Policy Vertebral Axial Decompression Section 8.0 Therapy Subsection 8.03 Rehabilitation. Description. Related Policies.
8.03.09 Vertebral Axial Decompression Section 8.0 Therapy Subsection 8.03 Rehabilitation Effective Date October 31, 2014 Original Policy Date June 28, 2007 Next Review Date October 2015 Description Vertebral
More informationSpecial Contribution Questions to and Answers from the International AIDS Society USA Resistance Testing Guidelines Panel
Special Contribution Questions to and Answers from the International AIDS Society USA Resistance Testing Guidelines Panel In 1996 the International AIDS Society USA convened an international panel of experts
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationBioimpedance Devices for Detection and Management of Lymphedema
2.01.82 Bioimpedance Devices for Detection and Management of Lymphedema Section 2.0 Medicine Subsection Effective Date January 30, 2015 Original Policy Date July 2, 2010 Next Review Date January 2015 Medical
More informationHIV-1 Subtypes: An Overview. Anna Maria Geretti Royal Free Hospital
HIV-1 Subtypes: An Overview Anna Maria Geretti Royal Free Hospital Group M Subtypes A (1, 2, 3) B C D F (1, 2) G H J K Mechanisms of HIV-1 genetic diversification Point mutations RT error rate: ~1 per
More informationHIV/AIDS CID 2003:37 (1 July) 113
MAJOR ARTICLE HIV/AIDS Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society USA Panel Martin S. Hirsch,
More informationThe Use of Resistance Testing in HIV
The Use of Resistance Testing in HIV Dushyantha Jayaweera, M.D., M.R.C.O.G., F.A.C.P. Professor in Clinical Medicine Division of Infectious Diseases University of Miami Miller School of Medicine Viral
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Trogarzo) Reference Number: CP.PHAR.378 Effective Date: 04.17.18 Last Review Date: 05.18 Line of Business: Commercial, HIM-Medical Benefit, Medicaid Coding Implications Revision Log See
More informationManagement of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More informationHIV Drug Resistance. Together, we can change the course of the HIV epidemic one woman at a time.
HIV Drug Resistance Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Is Resistance? HIV drugs are designed to keep the amount of HIV virus
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationNNRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER NNRTI Resistance David H. Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington Last Updated:
More informationORIGINAL ARTICLE /j x. Brescia, Italy
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.00938.x Prevalence of drug resistance and newly recognised treatment-related substitutions in the HIV-1 reverse transcriptase and protease genes from HIV-positive
More informationThe Danish HIV Cohort Study, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark 4
Antiviral Therapy 2009 14: 995 1000 (doi: 10.3851/IMP1412) Original article The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish
More informationHIV Drug Resistance: An Overview
Human Journals Review Article October 2015 Vol.:1, Issue:1 All rights are reserved by Suraj Narayan Mali et al. HIV Drug Resistance: An Overview Keywords: HIV drug resistance mechanism, Antiretroviral
More informationHIV replication and selection of resistance: basic principles
HIV replication and selection of resistance: basic principles 26th International HIV Drug Resistance and Treatment Strategies Workshop Douglas Richman 6 November 2017 CLINICAL DATA DURING SIXTEEN WEEKS
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationEvaluation and Management of Virologic Failure
National HIV Curriculum PDF created November 3, 2018, 12:26 am Evaluation and Management of Virologic Failure This is a PDF version of the following document: Section 1: Antiretroviral Therapy Topic 5:
More informationPolicy Specific Section: March 1, 2005 January 30, 2015
Medical Policy Fecal DNA Analysis for Colorectal Cancer Screening Type: Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date: Effective Date: March 1, 2005
More informationPolicy Specific Section:
Medical Policy Spinal Manipulation under Anesthesia Type: Investigational / Experimental Policy Specific Section: Medicine Original Policy Date: Effective Date: February 26, 1997 July 6, 2012 Definitions
More informationDoes Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Does Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosure The speaker serves as a consultant to, and has received
More informationTools to Monitor HIV Infection in 2013 and Beyond.
Tools to Monitor HIV Infection in 2013 and Beyond. Federico García, fegarcia@ugr.es Servicio de Microbiología Univ. Hospital San Cecilio Granada, Spain Outline Address clinical questions: Ultra sensitive
More informationQUANTITATIVE HIV RNA (VIRAL LOAD)
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS QUANTITATIVE HIV RNA (VIRAL LOAD) Policy Number: PDS - 008 Effective Date: October
More informationCase Study. Dr Sarah Sasson Immunopathology Registrar. HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital.
Case Study Dr Sarah Sasson Immunopathology Registrar HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital Case 1: Case 1: 45F in Cameroon Cameroon HIV+ Presents with cutaneous
More informationMagnetic Esophageal Ring to Treat Gastroesophageal Reflux Disease (GERD)
7.01.137 Magnetic Esophageal Ring to Treat Gastroesophageal Reflux Disease (GERD) Section 7.0 Surgery Effective Date January 30, 2015 Subsection Original Policy Date June 28, 2013 Next Review Date October
More informationScottish Medicines Consortium
Scottish Medicines Consortium raltegravir, 400mg film-coated tablet (Isentress) No. (461/08) Merck, Sharp and Dohme Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationInjectable Bulking Agents for the Treatment of Fecal Incontinence. Policy Specific Section: September 27, 2013 January 1, 2015
Medical Policy Injectable Bulking Agents for the Treatment of Fecal Incontinence Type: Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective Date: September 27,
More informationMDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007
MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus
More informationGenotypic Resistance in HIV-infected Patients Failing a d4t/3tc/nvp Regimen
Original Article Genotypic Resistance in HIV-infected Patients Failing a d4t/3tc/nvp Regimen Somnuek Sungkanuparph, M.D.* Weerawat Manosuthi, M.D.* Sasisopin Kiertiburanakul, M.D.* Wasun chantratita, Ph.D.**
More informationVosevi (sofosbuvir/velpatasvir/voxilaprevir)
Vosevi (sofosbuvir/velpatasvir/voxilaprevir) Policy Number: 5.01.646 Last Review: 10/2017 Origination: 10/2017 Next Review: 11/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide
More informationIt takes more than just a single target
It takes more than just a single target As the challenges you face evolve... HIV mutates No HIV-1 mutation can be considered to be neutral 1 Growing evidence indicates all HIV subtypes may be prone to
More informationSupervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis.
Supervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis. J.L. YOZVIAK 1, P. KOUVATSOS 2, R.E. DOERFLER 3, W.C. WOODWARD 3 1 Philadelphia College of Osteopathic
More informationDr Marta Boffito Chelsea and Westminster Hospital, London
Dr Marta Boffito Chelsea and Westminster Hospital, London Speaker Name Statement Dr Marta Boffito has received travel and research grants from and has been an advisor for Janssen, Roche, Pfizer, ViiV,
More informationThe influence of antiretroviral-resistance tests on treatment effectiveness in patients with HIV and virological failure
1130-6343/2007/31/1/23 FARMACIA HOSPITALARIA Copyright 2007 ARÁN EDICIONES, S. L. FARM HOSP Vol. 31. N. 7, pp. 23-29, 2007 ORIGINAL The influence of antiretroviral-resistance tests on treatment effectiveness
More informationTitle. HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in
Title HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance October 13, 2004 Authors SY Rhee
More informationEvaluation of genotype resistance testing for salvage antiretroviral therapy at AIDS care centers from Ribeirão Preto, São Paulo, Brazil
Genotype Brazilian Journal resistance of Medical testing and for salvage Biological ART Research (2008) 41: 533-538 ISSN 0100-879X 533 Evaluation of genotype resistance testing for salvage antiretroviral
More informationTerapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos
Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos (Antiretroviral Therapy Present and Future Prospects of Antiretroviral Drugs in Initial and Salvage Therapy)
More informationReverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review
pissn 2349-2910 eissn 2395-0684 REVIEW Reverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review Dinesh Bure, Department
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More information10 : 4. Introduction. R Sajithkumar, Kottayam. Mutations to select agents: Evolution:
10 : 4 HIV drug resistance and second line of ART Introduction The first response to the HIV epidemic identified as AIDS in 1981- was the feeling of helplessness. The cause of the illness was soon identified
More informationBecause accurate and reproducible phenotypic susceptibility
BRIEF REPORT: CLINICAL SCIENCE Comparison of the Precision and Sensitivity of the Antivirogram and PhenoSense HIV Drug Susceptibility Assays Jie Zhang, MS,* Soo-Yon Rhee, MS,* Jonathan Taylor, PhD, and
More informationTOXICITY, TOLERABILITY, AND ADHERENCE TO THERAPY
SAFETY AND TOLERABILITY OF CURRENTLY AVAILABLE ANTIRETROVIRAL AGENTS * Esteban Martinez, MD, PhD ABSTRACT Safety and tolerability are important factors to consider when instituting or modifying therapy
More informationLow-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution
J Antimicrob Chemother 2010; 65: 1322 1326 doi:10.1093/jac/dkq139 Advance Access publication 13 May 2010 Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted
More informationINTEGRASE INHIBITOR (INI) RESISTANCE IN HIV- POSITIVE PATIENTS UNDERGOING ROUTINE TESTING
INTEGRASE INHIBITOR (INI) RESISTANCE IN HIV- POSITIVE PATIENTS UNDERGOING ROUTINE TESTING Dr. Danni Kirwan ID/Microbiology SpR St. George s Hospital, London ARV initiation in treatment-naïve patients BHIVA,
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationPatients with persistently low CD4 counts on antiretroviral
Predicting HIV Care Costs Using CD4 Counts From Clinical Trials Andrew Hill, PhD; and Kelly Gebo, MD, MPH Objective: To predict the effects of a new antiretroviral agent on the costs of care in a US HIV
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationThe E138A substitution in HIV-1 reverse transcriptase decreases in vitro. susceptibility to emtricitabine as indicated by competitive fitness assays
AAC Accepts, published online ahead of print on 13 January 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.02114-13 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 The E138A
More informationAntiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationFrailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting. Giovanni Guaraldi
Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting Giovanni Guaraldi Potential conflicts of interest Research funding: Jansen, Gilead, MSD, BMS Consultancies:
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationLiver Toxicity in Epidemiological Cohorts
SUPPLEMENT ARTICLE Liver Toxicity in Epidemiological Cohorts Stephen Becker Pacific Horizon Medical Group, San Francisco, California Hepatotoxicity has been demonstrated to be associated with antiretroviral
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More informationClinical Management of HIV Drug Resistance
Viruses 2011, 3, 347-378; doi:10.3390/v3040347 OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Review Clinical Management of HIV Drug Resistance Karoll J. Cortez and Frank Maldarelli *
More informationBJID 2001; 5 (August) 177. count and a mild decrease in viral load, patients tended to have an inverse correlation between the CD 4. counts [7].
BJID 2001; 5 (August) 177 Evaluation of Viral Resistance to Reverse Transcriptase Inhibitors (RTI) in HIV-1- Infected Patients Before and After 6 Months of Single or Double Antiretroviral Therapy Carlos
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Xofluza) Reference Number: CP.PMN.185 Effective Date: 10.30.18 Last Review Date: 11.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationABC/3TC/ZDV ABC PBO/3TC/ZDV
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationLaboratory Tests for Heart Transplant Rejection Section 2.0 Medicine Subsection 2.01 Medicine
2.01.68 Laboratory Tests for Heart Transplant Rejection Section 2.0 Medicine Subsection 2.01 Medicine Description Effective Date February 15, 2015 Original Policy Date April 5, 2007 Next Review Date December
More informationClinical Implications of Mutations at Reverse Transcriptase Codon 135 on Response to NNRTI-Based Therapy
8 The Open Virology Journal, 2007, 1, 8-13 Clinical Implications of Mutations at Reverse Transcriptase Codon 135 on Response to NNRTI-Based Therapy Harout K. Tossonian 1, Jesse D. Raffa 2, Jason Grebely
More informationHistory (August 2010) Therapy for Experienced Patients. History (September 2010) History (November 2010) 12/2/11
(August 2010) Therapy for Experienced Patients Hiroyu Hatano, MD, MHS Assistant Professor of Medicine University of California San Francisco Medical Management of AIDS December 2011 42M HIV (CD4=450, VL=6250,
More informationQUANTITATIVE HIV RNA (VIRAL LOAD)
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS QUANTITATIVE HIV RNA (VIRAL LOAD) Policy Number: PDS - 008 Effective Date: January
More informationStructured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007
Structured Treatment Interruption in HIV Positive Patients Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Objectives To become re-acquainted with the basics of HAART for HIV infection
More informationPatterns of Resistance to Antiretroviral Therapy among HIV+ Patients in Clinical Care
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 11-15-2006 Patterns of Resistance to Antiretroviral Therapy among
More informationAntiviral Therapy 2013; 18: (doi: /IMP2329)
Antiviral Therapy 2013; 18:213 219 (doi: 10.3851/IMP2329) Original article Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationPrinciples of HIV Drug Resistance: Resistance to New Drug Classes. Mark A Wainberg McGill University AIDS Centre Montreal, Quebec, Canada
Principles of HIV Drug Resistance: Resistance to New Drug Classes Mark A Wainberg McGill University AIDS Centre Montreal, Quebec, Canada Why Is It Important to Understand HIV Drug Resistance? 1. Resistance
More informationHIV-1 DRUG RESISTANCE MUTATIONS IN CHILDREN WHO FAILED NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR-BASED ANTIRETROVIRAL THERAPY
HIV-1 DRUG RESISTANCE MUTATIONS IN CHILDREN HIV-1 DRUG RESISTANCE MUTATIONS IN CHILDREN WHO FAILED NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR-BASED ANTIRETROVIRAL THERAPY Somnuek Sungkanuparph 1, Nopporn
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Daraprim) Reference Number: CP.PMN.44 Effective Date: 11.01.15 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationClinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: HIM.PA.SP36 Effective Date: Last Review Date: 06.18
Clinical Policy: (Mavyret) Reference Number: HIM.PA.SP36 Effective Date: 08.01.17 Last Review Date: 06.18 Line of Business: HIM Revision Log See Important Reminder at the end of this policy for important
More informationPersistent low-level HIV-1 RNA between 20 and 50 copies/ml in antiretroviral-treated patients: associated factors and virological outcome
J Antimicrob Chemother 2012; 67: 2231 2235 doi:10.1093/jac/dks191 Advance Access publication 29 May 2012 Persistent low-level HIV-1 RNA between 20 and 50 copies/ml in antiretroviral-treated patients: associated
More informationDifferentiating emtricitabine (FTC) from lamivudine (3TC): what a fine-tuning of antiretroviral therapy might entail
HAART, HIV correlated pathologies and other infections Renato Maserati Differentiating emtricitabine (FTC) from lamivudine (3TC): what a fine-tuning of antiretroviral therapy might entail Corresponding
More informationOriginal article The cost of antiretroviral drug resistance in HIV positive patients
This pdf is for personal use only. To obtain commercial reprints, Antiviral Therapy: in press (doi: 10.3851/IMP2709) Original article The cost of antiretroviral drug resistance in HIV positive patients
More informationHIV associated CNS disease in the era of HAART
HIV associated CNS disease in the era of HAART CSF/CNS penetration and efficacy Acknowledgements Peter Portegies Department of Neurology, AMC Mark van der Valk Department of Internal Medicine/Infectious
More informationTreatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens
Send Orders for Reprints to reprints@benthamscience.ae 38 The Open AIDS Journal, 2015, 9, 38-44 Open Access Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationRole of Efavirenz in HIV-infected Patients with Preceding Nevirapine-related Skin Rash
Review Article Vol. 24 No. 2 Nevirapine-associated rashes:- Manosuthi W & Sungkanuparph S. 89 Role of Efavirenz in HIV-infected Patients with Preceding Nevirapine-related Skin Rash Weerawat Manosuthi,
More informationDoes GSS Still Maintain Relevance on HAART Outcome After the Introduction of Newest Active Antiretroviral Drugs? 48 Weeks Results
Current HIV Research, 2011, 9, 000-000 1 Does GSS Still Maintain Relevance on HAART Outcome After the Introduction of Newest Active Antiretroviral Drugs? 48 Weeks Results M. Ortu *,1, P. Vitiello 1, F.
More informationUpdate on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners
More informationClinical Policy: Valganciclovir (Valcyte) Reference Number: CP.CPA.116 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Valcyte) Reference Number: CP.CPA.116 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationMany highly active antiretroviral therapy PROCEEDINGS
MAXIMIZING THE EFFECTIVENESS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: IS THERE A ROLE FOR QUADRUPLE REGIMENS? * François Raffi, MD, PhD ABSTRACT Although many highly active antiretroviral therapy (HAART)
More informationDidactic Series. Archive Genotype Resistance Testing in the Setting of Regimen Switching
Didactic Series Archive Genotype Resistance Testing in the Setting of Regimen Switching Craig Ballard, Pharm.D., AAHIVP UCSD Medical Center Owen Clinic June 11, 2015 ACCREDITATION STATEMENT: University
More informationDNA Genotyping in HIV Infection
Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationCURRICULUM VITAE. Miguel Goicoechea, M.D.
CURRICULUM VITAE Miguel Goicoechea, M.D. Office: Telephone: University of California at San Diego Antiviral Research Center 150 West Washington Street, Suite 100 San Diego, CA 92103-2005 (619) 543-8080
More informationBroad Nucleoside Reverse-Transcriptase Inhibitor Cross-Resistance in Human Immunodeficiency Virus Type 1 Clinical Isolates
MAJOR ARTICLE Broad Nucleoside Reverse-Transcriptase Inhibitor Cross-Resistance in Human Immunodeficiency Virus Type 1 Clinical Isolates Jeannette M. Whitcomb, Neil T. Parkin, Colombe Chappey, Nicholas
More information